CORCYM
16.7.2021 09:02:12 CEST | Business Wire | Press release
CORCYM, the new, independent, medical device company dedicated to providing patients and cardiac surgeons with the best solutions to fight structural heart disease, announces today the enrollment of the first patient in the MANTRA study. MANTRA (M itral, A ortic aN d T ricuspid post-maR ket S tudy in a reA l-world setting) is a prospective, multi-arm, multi-center, global, post-market clinical follow-up study that monitors the safety and performance of the complete CORCYM portfolio in a real-world setting.
“The MANTRA study has been designed leveraging the umbrella study concept, as it contains a master protocol with endpoints applicable across the treatment options together with additional sub-studies for specific devices and dedicated endpoints. MANTRA currently contains three sub-studies: an aortic study, a mitral and tricuspid study, and a third study fully dedicated to the Memo 4D annuloplasty ring,” explained Prof. Bart Meuris (University Hospital Leuven, Belgium) Coordinating Investigator of the MANTRA aortic sub-study and part of the MANTRA Steering Committee together with Prof. Serdar Günaydın (Ankara City Hospital, Turkey), Prof. Jörg Kempfert (Deutsches Herzzentrum Berlin, Germany) and Prof. Patrizio Lancellotti (University Hospital Liège, CHU Sart Tilman, Belgium).
The first patient was implanted in Italy, at Città di Lecce Hospital with a Bicarbon aortic mechanical valve, which has been CE mark approved for use with low-dose anticoagulant therapy in low-risk patients1 . Conducted worldwide, the MANTRA study is planned to enroll 1,750 patients in approximately 100 centers with follow-up to 10 years.
“We are glad to take part in the MANTRA study and to have started enrolling patients in its aortic sub-study. As a primary endpoint, we will verify the device success at 30 days as defined by the VARC guidelines2 . Study patients will be followed-up annually to 10 years to assess the device safety and performance, together with the patient quality of life,” reported Dr. Giuseppe Santarpino , Principal Investigator at Città di Lecce Hospital, Italy.
“The launch of the MANTRA study confirms CORCYM’s commitment to continuously generate new clinical evidence in collaboration with cardiac surgeons to help them treat patients better today and in the future,” commented Christian Mazzi , CORCYM CEO.
About CORCYM
CORCYM is a global, independent, medical device company entirely focused on state-of-the-art surgical solutions to fight structural heart disease. CORCYM has a presence in more than 100 countries with approximately 850 employees and ensures strong continuous support to patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.corcym.com
___________________________
References:
- INR range 1.5-2.5 in patients at low risk for thromboembolic events undergoing single mechanical aortic valve replacement, as demonstrated by Torella et al., Am Heart J; 160:171-8, 2010.
- VARC: Valve Academic Research Consortium (Généreux, et al. 2021 Eur Heart J, 42(19):1825-1857).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210716005014/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Identifies the Life-Stage Insights Shaping Dairy’s Future6.10.2026 13:00:00 CEST | Press release
IFF (NYSE: IFF)—a global leader in flavors, fragrances and health and biosciences, published its latest resource, Dear Dairy: The Life Stages Guide. This strategic guide reveals how manufacturers can unlock new opportunities by aligning dairy innovation with consumers' evolving needs throughout life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005026164/en/ “Dairy is one of the few categories that evolves alongside consumers throughout their lives,” said Rogerio de Almeida Prado, vice president of Global Dairy & BBC (Bakery, Bars and Confectionery) for IFF Taste. “Over time, expectations change. What builds trust in childhood may need to support identity, convenience or vitality later in life. The next wave of dairy innovation will be defined not by a single trend, ingredient or claim, but by an understanding of what consumers need at different times of their lives — and why.” Drawing on insights from Panoptic™, IFF's
Invivoscribe® Advances Molecular Clonality Testing Portfolio with Comprehensive LymphoTrack® Flex Suite6.10.2026 12:15:00 CEST | Press release
New ultra-high sensitivity tests enable objective, automation-ready, high-throughput clonality and MRD workflow. Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced the launch of the complete LymphoTrack Flex suite, an integrated next-generation sequencing (NGS) solution to identify and track immunoglobulin and T-cell receptor gene rearrangements. As NGS-based immune receptor MRD analysis moves from academic laboratories into routine use in oncology research centers, the demand for standardized, high-throughput workflows is accelerating. Laboratories are seeking both greater efficiency and ultra-high sensitivity. This requires increasing DNA inputs while ensuring higher testing throughput and analytical performance. Translational programs need testing that is both reproducible and scalable across sites. LymphoTrack Flex meets these demands, bringing seven molecular targets (IGHV leader, IGH FR1, IGH FR2, IGH FR3, IGK, TR
Degreed Agents Enable Every Leader to Upskill Their Organization with Ease6.10.2026 12:00:00 CEST | Press release
Degreed was born with the mission to help everyone get credit for all of their learning and skills. Today, the company announces the latest phase of that journey with the release of Degreed agents, a connected system of AI agents that lets leaders and L&D teams automate personalized learning and skill building. Leaders set the direction, agents do the work, and together they form the foundation of a hybrid operating system for their workforce. Businesses today run workforce transformations as a relay. The CEO sets a mandate to get everyone AI-fluent. A talent leader then defines the end state while managers try to spot gaps on their own teams. L&D pulls reports by hand and builds what they can. Each handoff adds a delay. Now, agents can orchestrate all of that in real time. Degreed agents notice details that matter, like a promotion, a skill gap, or an engagement dip, and act on them without requiring a manager to notice, an admin to flag it, or L&D to build it. At launch, agents build
OPEX® Corporation Offers a Simplified, One-Touch Document Scanning Solution with the Introduction of Axis™6.10.2026 10:00:00 CEST | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of Axis™, a new document scanner that brings the benefits of one-touch scanning to a simplified, single-bin configuration. Designed for document capture workflows where minimal document preparation, mixed media handling or operational simplicity are priorities, Axis bridges the gap between OPEX’s desktop scanner series and its multi-bin production scanner portfolio. “We developed Axis in direct response to market demands,” said Dann Worrell, President, Document and Mail Automation, OPEX. “Our customers want to simplify their scanning processes, reduce operating costs, and improve quality. Axis delivers on these priorities by combining our minimal-prep, One-Touch scanning technology with a single-bin design. With a lower market accessible entry point, Axis helps customers process documents more efficiently while achieving m
Rothera Goes Live on Smartstream’s Air to Automate High-Volume Derivatives Reconciliations6.10.2026 10:00:00 CEST | Press release
Key Facts - Rothera, a derivatives exchange and clearinghouse regulated by the U.S. Commodity Futures Trading Commission (CFTC), has gone live on Smartstream’s Air, deploying the Cash and Data modules to automate its reconciliation operations. - The new implementation replaces manual processes, enabling Rothera to reconcile circa 1.7 million daily transactions within a fully automated, fully audited environment. - Go-live for two data reconciliations: Exchange-to-Clearing Instruments and Exchange-to-Clearing Trades – with further reconciliation flows to follow. Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announced that Rothera, the U.S.-based CFTC-regulated event contract market, has gone live on Smartstream’s Air. Rothera has deployed Smartstream’s Cash and Data modules to automate high-volume derivatives reconciliations across its CFTC-regulated exchange and clearinghouse business. As transaction volumes on the exc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom